Advanced in Schizoaffective Disorder

Dr. Otto R. Dueno

Psychiatry | Geriatrics
Kettering Independent Medical Group Inc
5350 Lamme Rd, 
Moraine, OH 
Accepting New Patients
Offers Telehealth
Advanced in Schizoaffective Disorder
Kettering Independent Medical Group Inc
5350 Lamme Rd, 
Moraine, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Otto Dueno is a Psychiatrist and a Geriatrics provider in Moraine, Ohio. Dr. Dueno is rated as an Advanced provider by MediFind in the treatment of Schizoaffective Disorder. His top areas of expertise are Major Depression, Bipolar Disorder (BPD), Seasonal Affective Disorder (SAD), and Generalized Anxiety Disorder (GAD). Dr. Dueno is currently accepting new patients.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Psychiatry
Geriatrics
Licenses
Psychiatry & Neurology in OH
Hospital Affiliations
Kettering Health Miamisburg
Languages Spoken
English
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Health
  • HMO
  • PPO
Medical Mutual
  • HMO
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 17 Less Insurance Carriers -

Locations

KETTERING INDEPENDENT MEDICAL GROUP INC
5350 Lamme Rd, Moraine, OH 45439
Other Locations
2621 Dryden Rd, Suite 100, Moraine, OH 45439
KETTERING INDEPENDENT MEDICAL GROUP INC
4403 Far Hills Ave, Kettering, OH 45429

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 2a, Randomized, Double-blind, Placebo-controlled Proof of Concept Study to Evaluate the Effects of Oral BTRX-335140 (NMRA-335140) Versus Placebo in Subjects With Major Depressive Disorder
A Phase 2a, Randomized, Double-blind, Placebo-controlled Proof of Concept Study to Evaluate the Effects of Oral BTRX-335140 (NMRA-335140) Versus Placebo in Subjects With Major Depressive Disorder
Enrollment Status: Completed
Publish Date: May 29, 2025
Intervention Type: Drug
Study Drug: BTRX-335140
Study Phase: Phase 2
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety and Efficacy of IXT-m200 in Treatment-Seeking Individuals With Methamphetamine Use Disorder
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety and Efficacy of IXT-m200 in Treatment-Seeking Individuals With Methamphetamine Use Disorder
Enrollment Status: Terminated
Publish Date: October 04, 2024
Intervention Type: Drug, Other
Study Phase: Phase 2
Phase 2a Multicenter Randomized Double-Blind Placebo-Controlled Study to Assess the Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing of REL-1017 as Adjunctive Therapy in the Treatment of Pts Diagnosed With MDD
Phase 2a Multicenter Randomized Double-Blind Placebo-Controlled Study to Assess the Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing of REL-1017 as Adjunctive Therapy in the Treatment of Pts Diagnosed With MDD
Enrollment Status: Completed
Publish Date: November 01, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of CX-8998 for Essential Tremor
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of CX-8998 for Essential Tremor
Enrollment Status: Completed
Publish Date: November 23, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase IIIb Multi-Center, Open-Label, Mirror-Image, Trial in Adult Subjects With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®
A Phase IIIb Multi-Center, Open-Label, Mirror-Image, Trial in Adult Subjects With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®
Enrollment Status: Terminated
Publish Date: September 05, 2021
Intervention Type: Combination product
Study Drug: ABILIFY MYCITE
Study Phase: Phase 3
A Multicenter, Dose-Optimized, Open-Label Safety Study With KP415 in Children With Attention-Deficit/Hyperactivity Disorder
A Multicenter, Dose-Optimized, Open-Label Safety Study With KP415 in Children With Attention-Deficit/Hyperactivity Disorder
Enrollment Status: Completed
Publish Date: July 19, 2021
Intervention Type: Drug
Study Phase: Phase 3
An 8-Week Prospective Randomized, Controlled, Double-Blind Trial of the Genecept Assay ™ vs. Treatment-as-Usual to Evaluate Efficacy of Assay-Guided Treatment in Adults With Major Depressive Disorder (MDD)
An 8-Week Prospective Randomized, Controlled, Double-Blind Trial of the Genecept Assay ™ vs. Treatment-as-Usual to Evaluate Efficacy of Assay-Guided Treatment in Adults With Major Depressive Disorder (MDD)
Enrollment Status: Completed
Publish Date: August 28, 2020
Intervention Type: Genetic, Other
Study Phase: Not Applicable
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Single Doses of NV-5138 in Healthy Volunteers and Subjects With Treatment-Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Single Doses of NV-5138 in Healthy Volunteers and Subjects With Treatment-Resistant Depression
Enrollment Status: Completed
Publish Date: July 09, 2019
Intervention Type: Drug
Study Phase: Phase 1
CSD170304: An Unblinded, Parallel, Randomized Study to Assess Nicotine Uptake in Smokers From Electronic and Combustible Cigarettes
CSD170304: An Unblinded, Parallel, Randomized Study to Assess Nicotine Uptake in Smokers From Electronic and Combustible Cigarettes
Enrollment Status: Completed
Publish Date: November 14, 2017
Intervention Type: Other
Study Phase: Not Applicable
A Phase 2, Double-Blind, Placebo-Controlled Study of NSI-189, a Neurogenic Compound Among Out-Patients With Major Depressive Disorder
A Phase 2, Double-Blind, Placebo-Controlled Study of NSI-189, a Neurogenic Compound Among Out-Patients With Major Depressive Disorder
Enrollment Status: Unknown
Publish Date: February 24, 2017
Intervention Type: Drug
Study Drug: NSI-189
Study Phase: Phase 2
View 9 Less Clinical Trials

1 Total Publications

A Phase 2, multicenter, double-blind, randomized, placebo-controlled study of the safety and efficacy of forvisirvat (SP-624) in the treatment of adults with major depressive disorder.
A Phase 2, multicenter, double-blind, randomized, placebo-controlled study of the safety and efficacy of forvisirvat (SP-624) in the treatment of adults with major depressive disorder.
Journal: Current medical research and opinion
Published: October 16, 2025
Similar Doctors
Distinguished in Schizoaffective Disorder
Dr. Kalpana K. Vishnupad
Psychiatry | Geriatrics
Distinguished in Schizoaffective Disorder
Dr. Kalpana K. Vishnupad
Psychiatry | Geriatrics

Mental Health Services For Clark Co Inc

2501 E High St, 
Springfield, OH 
 (28.9 miles away)
937-390-7980
Languages Spoken:
English, Italian
See accepted insurances
Accepting New Patients
Offers Telehealth

Kalpana Vishnupad is a Psychiatrist and a Geriatrics provider in Springfield, Ohio. Dr. Vishnupad is rated as a Distinguished provider by MediFind in the treatment of Schizoaffective Disorder. Her top areas of expertise are Bipolar Disorder (BPD), Schizoaffective Disorder, Seasonal Affective Disorder (SAD), and Major Depression. Dr. Vishnupad is currently accepting new patients.

Distinguished in Schizoaffective Disorder
Dr. Sumera T. Khan
Psychiatry
Distinguished in Schizoaffective Disorder
Dr. Sumera T. Khan
Psychiatry
5604 Winding Cape Way, 
Mason, OH 
 (25.9 miles away)
513-339-0786
Languages Spoken:
English, Urdu
See accepted insurances
Accepting New Patients

Sumera Khan is a Psychiatrist in Mason, Ohio. Dr. Khan is rated as an Advanced provider by MediFind in the treatment of Schizoaffective Disorder. Her top areas of expertise are Schizoaffective Disorder, Bipolar Disorder (BPD), Major Depression, and Schizophrenia. Dr. Khan is currently accepting new patients.

Distinguished in Schizoaffective Disorder
Dr. Bryan J. Griffin
Psychiatry
Distinguished in Schizoaffective Disorder
Dr. Bryan J. Griffin
Psychiatry

University Of Cincinnati Physicians Company LLC

7700 University Dr, 
West Chester, OH 
 (23.4 miles away)
513-298-7325
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Bryan Griffin is a Psychiatrist in West Chester, Ohio. Dr. Griffin is rated as an Advanced provider by MediFind in the treatment of Schizoaffective Disorder. His top areas of expertise are Schizoaffective Disorder, Schizophrenia, Bipolar Disorder (BPD), and Major Depression. Dr. Griffin is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dueno's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile